拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02592 拨康视云-B

停牌 11-06 09:20:42

1.190

+0.000

0.00%

最高1.190	最低1.190	成交量0.00
今开1.190	昨收1.190	日振幅0.00%
总市值11.01亿	流通市值11.01亿	总股本9.25亿
成交额0.00	换手率0.00%	流通股本9.25亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":1.19,"timestamp":1793928042831,"preClose":1.19,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":925000000,"shares":925000000,"eps":-0.103023,"marketStatus":"停牌","change":0,"latestTime":"11-06 09:20:42","open":1.19,"high":1.19,"low":1.19,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.024,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.19,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.369999998816,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"1173436806","title":"拨康视云-B（02592）公布CBT-001治疗翼状胬肉III期顶线结果 两大主要终点均达显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1173436806","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173436806?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:12","pubTimestamp":1793837565,"startTime":"0","endTime":"0","summary":"11月5日，拨康视云-B自愿披露用于翼状胬肉的候选药物CBT-001全球多中心、随机、双盲、安慰剂对照III期试验顶线数据。两项主要疗效终点均达到显著统计学意义，成为目前首个在翼状胬肉治疗中显示明确疾病改善的药物候选项目。本次III期试验共入组659名翼状胬肉患者，其中CBT-001 0.1%组164例、0.2%组329例，安慰剂对照组166例；受试者中男性占58%，女性占42%。根据香港联交所指令，拨康视云-B股份自2026年9月10日起继续停牌，直至另行通知。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681921570","title":"拨康视云-B(02592)：CBT-001用于翼状胬肉患者的第3期研究顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2681921570","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681921570?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:09","pubTimestamp":1793837367,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，CBT-001作为翼状胬肉潜在疗法的第3期研究顶线结果。两大主要终点均获得显著统计学意义。对比安慰剂对照组在第3个月的结膜充血及第12个月的翼状胬肉病变长度，CBT-001的两种剂量展示出具高度统计学意义的改善情况。该等结果标志着首次有药物透过在统计学上显著改善充血及病变大小，展现出对翼状胬肉的疾病治疗作用。其他分析正在进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103453820","title":"拨康视云-B更新2026年10月股份变动月报表，股本稳定无新增发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1103453820","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103453820?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:46","pubTimestamp":1793803567,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc.于2026年11月4日披露了截至2026年10月31日的月度股份变动情况。本次月报显示，公司法定/注册股本维持在2,000,000,000股，对应注册股本总额为200,000美元，与上月一致。截至2026年10月底，拨康视云-B已发行普通股数量保持在924,692,316股，无库存股份，合计发行股份总数较上月无变化。公司确认截至报告期末，符合香港联交所要求的最低公众持股量。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678513859","title":"中签不等于赚钱，港股IPO热潮“降温”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678513859","media":"第一财经资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678513859?lang=zh_cn&edition=full","pubTime":"2026-10-25 19:10","pubTimestamp":1792926605,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/LA40E55Q0519DDQ2.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/LA40E55Q0519DDQ2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["BK1616","02592","02479","BK1100","BK1155","02041","06157","02555","BK1161","BK1233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678128187","title":"香港IPO热潮“降温”：从推迟上市到散户认购不足","url":"https://stock-news.laohu8.com/highlight/detail?id=2678128187","media":"第一财经资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678128187?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:47","pubTimestamp":1792918032,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/LA3O8H3O0519DDQ2.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/LA3O8H3O0519DDQ2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["06157","02592","02479","BK1616","BK1155","BK1233","02555","BK1100","BK1161","02041"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675316789","title":"拨康视云涉嫌IPO欺诈：已停牌1个月 市值仅11亿 龚虹嘉曾亏超5000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2675316789","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675316789?lang=zh_cn&edition=full","pubTime":"2026-10-14 15:10","pubTimestamp":1791961803,"startTime":"0","endTime":"0","summary":"眼科生物科技公司拨康视云（股票代码：“2592”，简称：“拨康视云”）日前已停牌超过1个月。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261014/6392758739961476895335601.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261014/6392758739961476895335601.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35387/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["IPOS","REDS","02592","KCE","BK4127","BK1161","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675926233","title":"刚刚，SFC严查IPO造市，茶百道、拨康视云等三家企业中招","url":"https://stock-news.laohu8.com/highlight/detail?id=2675926233","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675926233?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:10","pubTimestamp":1791947400,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。2026年10月13日，香港证监会突然亮剑，一口气把三个已经上市的“问题学生”拉到台前，茶百道、拨康视云、天聚地合，桩桩件件都指向同一个词，IPO造市。本次调查为IPO 配售涉嫌人为造市，监管怀疑外部集团通过资金回流充当新股承配人，制造虚假认购热度；46 亿港元冻结资产归属涉案外部主体。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-10-14/doc-iniveefr8554913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1616","02592","KCE","IPOS","BK1161","REDS","BK1233","FRHC","BK4127","02555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127062026","title":"拨康视云-B2026年9月股份变动月报表：股本结构保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1127062026","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127062026?lang=zh_cn&edition=full","pubTime":"2026-10-06 19:27","pubTimestamp":1791286058,"startTime":"0","endTime":"0","summary":"拨康视云-B于2026年10月6日发布了截至2026年9月30日的证券变动月报表。公告显示，公司在本月并未发生新增股份发行、股份购回、注销或库存股份变动，公司股本结构维持不变。根据公告，拨康视云-B截至2026年9月底的法定/注册股本维持为2,000,000,000股普通股，面值均为每股0.0001美元，总注册股本为200,000美元。公司表示，截至本月末，已满足香港联交所相关规定的最低公众持股量要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671263788","title":"拨康视云：股票继续暂停买卖","url":"https://stock-news.laohu8.com/highlight/detail?id=2671263788","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671263788?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:05","pubTimestamp":1790777142,"startTime":"0","endTime":"0","summary":"南财智讯9月30日电，拨康视云（02592.HK）公告，公司董事会决议成立独立特别委员会，以进行及监督有关证监会关注事项的内部调查。由于需要额外时间完成内部调查及落实2026年中期报告的内容，公司无法于2026年9月30日或之前刊发及寄发2026年中期报告。公司股份自2026年9月10日起暂停买卖，并将继续暂停直至另行通知为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609303887916514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609303887916514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165933956","title":"拨康视云-B设立独立特委会并推迟发布2026年中期报告，股份继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1165933956","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165933956?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:55","pubTimestamp":1790776543,"startTime":"0","endTime":"0","summary":"拨康视云-B9月30日公告称，董事会已于2026年9月30日决议成立独立特别委员会，由2026年9月23日获委任的独立非执行董事陈上仁先生及季诗杰先生组成，负责就2026年9月23日公告所述证券及期货事务监察委员会关注事项展开并监督内部调查，并处理相关事宜。公司表示，将适时向股东及潜在投资者披露调查结果。此外，依据证券及期货事务监察委员会的指令，联交所已自2026年9月10日09:00起暂停公司股份买卖，停牌状态将持续至另行通知为止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671009592","title":"拨康视云-B(02592)成立独立特别委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=2671009592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671009592?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:54","pubTimestamp":1790776493,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，于2026年9月30日，董事会议决成立独立特别委员会，由陈上仁先生及季诗杰先生(均为于2026年9月23日获委任的独立非执行董事)组成，以根据本公司日期为2026年9月23日的公告进行及监督有关证监会所关注事项的内部调查(内部调查)，并处理任何必要的相关事宜。为确保完全公正并增强公众信心，独立特别委员会由该等新获委任的独立非执行董事组成。本公司将适时向其股东及潜在投资者更新内部调查的结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146575851","title":"拨康视云-B（02592）公布最新董事会及委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1146575851","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146575851?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:15","pubTimestamp":1790172959,"startTime":"0","endTime":"0","summary":"2026年9月23日，拨康视云制药有限公司发布公告，更新自2026年9月23日起生效的董事会及其下属委员会成员名单。公告特别标注「C」代表委员会主席，「M」代表委员会成员。公司在公告中未披露新的财务数据或经营指标，本次信息披露仅涉及董事会及其委员会成员调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123095851","title":"拨康视云-B(02592)委任两名独立非执行董事　交易继续暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=1123095851","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123095851?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:11","pubTimestamp":1790172705,"startTime":"0","endTime":"0","summary":"2026年9月23日，拨康视云-B公告称，董事会已委任陈上仁先生及季诗杰先生为独立非执行董事，任期自2026年9月23日起，初始期限为三年，需在股东周年大会上轮值退任及获重选。双方可提前不少于30日书面通知终止委任，但终止日期不得早于首次股东周年大会召开前。根据证监会指令，拨康视云-B股份自2026年9月10日09:00起已暂停买卖，并将继续暂停，直至另行通知。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669248145","title":"拨康视云-B(02592)：陈上仁及季诗杰获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669248145","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669248145?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:09","pubTimestamp":1790172568,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，陈上仁先生及季诗杰先生已获委任为独立非执行董事，自2026年9月23日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177850419","title":"拨康视云-B聚焦多条核心产品线 推进临床试验与全球商业化规划","url":"https://stock-news.laohu8.com/highlight/detail?id=1177850419","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177850419?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:46","pubTimestamp":1789742797,"startTime":"0","endTime":"0","summary":"拨康视云-B于截至2025年12月31日止年度，聚焦多款眼科药物管线的临床进展及后续商业化规划。公司公布，核心产品CBT-001的多地临床试验已完成，并正进行数据整理与锁库，后续计划向美国食品及药物管理局及国家药品监督管理局提交潜在新药申请，目标于2030年至2032年间在美国实现商业化。针对儿童近视视过敏症的药物CBT-009目前则推进第三期多地临床试验，已制订全球临床实施计划，预计在2032年至2034年间于美国开展商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拨康视云-B聚焦多条核心产品线 推进临床试验与全球商业化规划","news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125126957","title":"拨康视云-B（02592）因IPO疑遭操纵自9月10日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1125126957","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125126957?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:45","pubTimestamp":1789742731,"startTime":"0","endTime":"0","summary":"香港，2026年9月18日——拨康视云-B今日公告称，已接获香港证券及期货事务监察委员会指令，股份自2026年9月10日9时起暂停买卖，停牌将持续至另行通知为止。证监会根据《证券及期货规则》第8条发出该指令。拨康视云-B董事会表示，正就指令及相关事宜寻求法律意见，并将全力配合证监会调查。公司提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668487709","title":"港股IPO风险深扒①｜拨康视云停牌核查：发行数据里的异常信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2668487709","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668487709?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:50","pubTimestamp":1789714200,"startTime":"0","endTime":"0","summary":"拨康视云回顾：上市首日破发38.6% 但发行环节的信号比股价更早暴露拨康视云发行价10.1港元，募资总额6.12亿港元，按照18A规则以未盈利生物医药企业身份上市。值得注意的是，拨康视云启动招股时，仍使用的是旧的回拨机制。拨康视云的公开发售倍数达到78.78倍，远超回拨门槛，但国际配售并未足额认购。拨康视云作为高波动的未盈利药企，没有设置绿鞋，上市后股价波动完全交给二级市场。拨康视云并非孤例。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-18/doc-inisfprf0294676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCAI","BK4127","REDS","BK4588","IPOS","BK1161","FRHC","VXUS","02592","KCE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668956305","title":"新股遭疯抢却上市即破发，14个月暴跌88％！拨康视云疑因IPO操纵被香港证监会停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2668956305","media":"华夏时报网","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668956305?lang=zh_cn&edition=full","pubTime":"2026-09-17 12:25","pubTimestamp":1789619112,"startTime":"0","endTime":"0","summary":"港股市场出现一起罕见的监管个案。一只上市前散户疯狂申购的18A眼科创新药新股，上市首日便遭遇破发，此后14个月股价大幅回撤，累计跌幅高达88%。这只股票便是拨康视云-B（02592.HK）。香港证监会对其IPO阶段可能存在人为操纵、刻意制造股份需求假象的情况表示严重关注，并指令该股暂停交易。目前相关调查仍在推进，监管尚未对公司是否存在违法违规行为作出最终认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609173877170256.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609173877170256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","REDS","02592","KCE","BK4127","BK1161","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667562662","title":"IPO涉嫌被人为操纵 港股药企拨康视云被暂停交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2667562662","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667562662?lang=zh_cn&edition=full","pubTime":"2026-09-14 23:05","pubTimestamp":1789398341,"startTime":"0","endTime":"0","summary":"9月10日，香港证监会官网披露消息称，因涉嫌操纵首次公开招股行为而暂停拨康视云（2592.HK）的股份交易。香港证监会官网披露消息称，因涉嫌操纵首次公开招股行为而暂停拨康视云的股份交易。来源：香港证监会官网上述消息称，香港证监会对拨康视云IPO可能曾被人为操纵，以营造对拨康视云股份需求的假象表示严重关注。因此，香港证监会认为，在继续进行调查期间，暂停有关股份的交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873769849.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873769849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KCE","IPOS","BK1161","02592","KCAI","BK4585","BK4588","REDS","VXUS","FRHC","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628946","title":"IPO涉嫌人为操纵！拨康视云被停牌调查，股价破发超八成","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628946","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667628946?lang=zh_cn&edition=full","pubTime":"2026-09-14 22:58","pubTimestamp":1789397893,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/L6QR6DGC05129QAF.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/L6QR6DGC05129QAF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.0165},{"period":"6month","weight":-0.2171},{"period":"1year","weight":-0.743},{"period":"ytd","weight":-0.7712}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云-B,02592,拨康视云-B股票,拨康视云-B股票老虎,拨康视云-B股票老虎国际,拨康视云-B行情,拨康视云-B股票行情,拨康视云-B股价,拨康视云-B股市,拨康视云-B股票价格,拨康视云-B股票交易,拨康视云-B股票购买,拨康视云-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}